Actualités

Q2 earnings and buybacks put Cigna Group in focus Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total...

A half-trillion-dollar valuation works out to about $208 a share. Shares have already traded within about 55 cents of it.

CoreWeave (NasdaqGS:CRWV) has expanded its AI cloud partnership with trading firm IMC, which is scaling up capacity for advanced financial trading workloads. IMC is moving from initial production use of CoreWeave to a materially larger capacity agreement focused on high intensity AI and machine learning tasks. Jane Street is reportedly refinancing about US$11b in debt with an eye on AI investments after previously committing significant capital to CoreWeave. The two trading firms' moves...

Tokenomics are a bigger factor than capital inflows here.

General Dynamics (GD) has drawn investor attention after reporting Q2 2026 results that exceeded consensus expectations, supported by revenue and earnings growth across all four segments and a record company backlog. See our latest analysis for General Dynamics. The Q2 beat, record US$136.5b backlog and recent contract win for General Dynamics Information Technology have coincided with a 90 day share price return of 13.14%, while the 5 year total shareholder return of 119.50% shows strong...

In early August 2026, Halozyme Therapeutics, Inc. reported record second‑quarter results, with revenue rising to US$481 million and net income to US$229.91 million, and raised its full‑year 2026 revenue guidance to a range of US$1.84 billion to US$1.91 billion. The company also accelerated capital returns by completing US$750 million of share repurchases under a 2024 authorization and buying an additional US$175.01 million of stock under a new 2026 program, while signing five new...

This boring high-yield stock just keeps going as it serves the world's changing energy needs.

Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and diabetes...

Two semiconductor ETFs hold nearly identical stocks, yet one has left the other in the dust this year by a staggering margin. The difference has nothing to do with which chips are inside and everything to do with how the fund is built.

Non-discretionary vesting event reduces his direct holdings by 4%, yet Stewart maintains a $4.89 million equity stake in the semiconductor firm.

The home improvement giant has significantly underperformed its bigger retail peer in the past five years.

They are going through a rough patch, but it's too early to give up on them.

Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...

Tariffs, earnings and guidance put First Solar stock in focus First Solar (FSLR) has moved into the spotlight after the U.S. administration approved a 15% tariff and minimum import prices on polysilicon products. This policy treats its thin film technology differently from silicon based rivals. The company publicly backed the new trade measures, which target reliance on Chinese polysilicon supply chains and support domestic manufacturing. Investors are weighing how this policy backdrop...

It's not much of a rivalry yet.

Advanced Micro Devices, Inc. (NASDAQ:AMD) just announced an acquisition that could give major competition to NVIDIA Corporation (NASDAQ:NVDA) in AI-inference. On August 6, AMD said it has agreed to buy chip startup Taalas as specialized inference chips become a critical area of focus for semiconductor makers. The financial terms of the deal have not been […]

SoFi Plus hit 200K paid members in one quarter. CEO Anthony Noto wants 1 million within a year. Here's why that target matters for SOFI stock.

Druckenmiller only owns one "Magnificent Seven" stock.

In the second quarter of 2026, Sunrun Inc. reported US$543.73 million in sales and US$869.99 million in revenue, with net income of US$115.15 million and a US$15 million non-cash impairment of energy systems, while also pricing a US$267 million securitization of residential solar assets. Despite lowering full-year cash generation guidance, Sunrun combined a strong earnings surprise, record storage attachment rates, and improved financing access to highlight progress in its solar-plus-storage...

The company has a long track record of quarterly dividend increases.

Warner Bros. Discovery (NasdaqGS:WBD) is set to be acquired by Paramount in a $110b deal that has now received regulatory approval in the United Kingdom. The UK Competition and Markets Authority and the British culture secretary have cleared the transaction, removing one of the last major regulatory obstacles. This approval follows similar clearances in other major jurisdictions ahead of expected U.S. antitrust proceedings. The decision adds clarity for Warner Bros. Discovery investors,...

Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher price target in the latest analyst run. Much of Wall Street commentary around this shift ties to recent Q2 beats, raised guidance, and differing views on how durable the current growth and pipeline story really is. As you read on, you will see how these moving pieces shape the evolving Amgen narrative and what to watch next in the research. Stay updated...

S&P 500 earnings just shattered a record that has stood since 2008, but two tech giants are responsible for a distortion that changes everything investors think they know about this earnings season.

Earnings, Dividend and Buyback Put Hilton Worldwide Holdings in Focus Hilton Worldwide Holdings (HLT) has drawn investor attention after reporting second quarter 2026 results, reaffirming its regular cash dividend and updating progress on a long running share repurchase program. For the second quarter ended June 30, 2026, Hilton Worldwide Holdings reported revenue of US$3,341 million compared with US$3,137 million a year earlier. Net income was US$482 million, with basic earnings per share...

Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising full year revenue guidance and updating progress on its share repurchase programs. For the quarter ended June 30, 2026, revenue was reported at US$481 million compared with US$325.72 million for the same period a year earlier. Net income for the quarter was US$229.91 million compared with US$165.16 million a year ago. Basic...

Abbott Laboratories buyback update Abbott Laboratories (ABT) has completed a share repurchase tranche that saw the company buy back 14,015,097 shares for about US$1.35b, including 11,599,094 shares between April and June 2026. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares trade at US$107.81 and have gained 27.86% over the past 90 days, while the year-to-date share price return is down 13.19% and the 1-year total shareholder return is down 17.86%. This points to...

Pinterest stock looks like a bargain following its latest post-earnings sell-off.

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

One generates 20% net margins on $12.2B in revenue; the other pulls $10.8B in free cash flow despite a 1.7x debt load.

DaVita stock has climbed 69.6% over the past three years. After a recent pullback and a strong value score, the current price still raises questions about how much upside investors are actually paying for. Over the past 3 years, DaVita has returned 69.6%, which puts recent share price weakness in the context of a longer period of strong gains. Support for the valuation can come from expectations that DaVita benefits from growing demand for integrated kidney and metabolic care. Execution...